ライフサイエンスコーパス: MMP-9

1 the activity of matrix metalloproteinase 9 (MMP-9).

2 L, and matrix metalloproteinases (MMP-2 and MMP-9).

3 etic ablation of matrix metalloproteinase-9 (MMP-9).

4 ) and a protease, matrix metallopeptidase 9 (MMP-9).

5 clastogenesis is matrix metalloproteinase 9 (MMP-9).

6 rget gene encoding matrix metalloprotease 9 (MMP-9).

7 ity of secreted matrix metalloproteinases 9 (MMP-9).

8 matrix metalloproteinases 2 and 9 (MMP-2 and MMP-9).

9 contrast to NMDAR-dependent LTP regulated by MMP-9.

10 e rescued by exogenous application of active MMP-9.

11 eIF4E phosphorylation and the expression of MMP-9.

12 tly inhibited in vivo expression of FGF2 and MMP-9.

13 A1 region, whereas nmdaLTP depends solely on MMP-9.

14 n and specifically preventing its binding to MMP-9.

15 DC/NHS for immobilization of monoclonal anti-MMP-9.

16 ionally activating E-cadherin and repressing MMP-9.

17 vity of matrix metalloproteinase (MMP)-3 and MMP-9.

18 observed within 5 min after the addition of MMP-9.

19 parallel cell-specific activity of MMP-2 and MMP-9.

20 that the improved outcomes are mediated via MMP-9.

21 oxidase-derived reactive oxygen species and MMP-9.

22 s increased expression of p16Ink4a, p21, and MMP-9.

23 1beta, and the pro-invasive metalloprotease, MMP-9.

24 rescein-conjugated gelatin by MMP-2, but not MMP-9.

25 ase-1 and -2; and depressed active and total MMP-9.

26 Recombinant human (rh) MMP-9 (10 or 20 mul; 0, 12.5, 25, 50, 100, 200, 500, and

27 th expression of matrix metalloproteinase 9 (MMP-9), a marker of fast MNs.

28 Pharmacologic inhibition of MMP-9 abrogated the difference in chemotactic attraction

29 plasticity of dendritic spines by triggering MMP-9 activation and ECM remodelling.

30 Liver metastasis along with MMP-9 activation and the production of inflammatory cyto

31 BV2 mouse microglia cell line and inhibited MMP-9 activation in primary microglia.

32 Our study shows that MCV sT-mediated MMP-9 activation is driven through the LSD, a known E3 l

33 ain Results: Neutrophil elastase, MMP-2, and MMP-9 activities and protein levels were equally elevate

34 0-60 min, likely independent of gelatinase B/MMP-9 activities.

35 l as on the corresponding intrinsic cellular MMP-9 activities.

36 ing heroin-paired cues transiently increased MMP-9 activity around D1-MSN dendritic spines and synaps

37 s from eight selected legume species towards MMP-9 activity in colon carcinoma cells.

38 mulates matrix metalloprotease-2 (MMP-2) and MMP-9 activity in the extracellular space.

39 t toward attenuating tumor progression where MMP-9 activity is strongly implicated.

40 MMP-9 activity is strongly related to cancer growth and

41 These findings suggest that increasing islet MMP-9 activity might be a strategy to limit beta-cell lo

42 LRx induces an increase in MMP-9 activity that is perisynaptic and enriched at thal

43 MMP-9 activity was analyzed by zymography.

44 e-induced periodontitis (P > 0.05); however, MMP-9 activity was lower in the group treated with desip

45 nd breakdown of TJPs, secondary to increased MMP-9 activity which suggests that these pathways are po

46 y addition of exogenous Shh, or neutralizing MMP-9 activity, decreased permeability and increased TJP

47 hness, and both appeared suitable to monitor MMP-9 activity.

48 the potential for matrix metalloprotease-9 (MMP-9), an endopeptidase secreted in response to neurona

49 the activity of matrix metalloproteinase 9 (MMP-9), an enzyme involved in extracellular matrix (ECM)

50 he conjoint increased expression of GFAP and MMP-9 and a purinergic ATP (P2) receptor antagonist redu

51 n induced a significant increase in secreted MMP-9 and an accumulation of cytoplasmic MMP-2 over time

52 city (Rmax) and Gb values for interaction of MMP-9 and anti-MMP-9 were 0.4nM, 680 microRIU and -53.51

53 nosorbent assay was used to assess levels of MMP-9 and IL-1beta in peri-implant sulcular fluid.

54 ient was used to analyze for correlations of MMP-9 and IL-1beta levels with peri-implant parameters.

55 The differential expression of MMP-9 and its regulatory factors is also examined.

56 gulation of known downstream targets such as MMP-9 and KISS1.

57 ith the iNPH group (p < 0.001), while MMP-2, MMP-9 and MMP-12 did not differ between the groups.

58 development genes, matrix metalloproteinases mmp-9 and mmp-13, while cortisol led to stronger upregul

59 This study investigates the expression of MMP-9 and MMP-2 in aggressive extracranial AVMs.

60 n of matrix metalloproteinases (MMPs), i.e., MMP-9 and MMP-2, and upregulation of tissue inhibitors o

61 Serum MMP-9 and MPO levels were higher in women with PCOS and

62 Salivary MMP-9 and NE levels, as well as MMP-9/TIMP-1 ratios, wer

63 miscuous E3 ligases, including FBW7, a known MMP-9 and Snail regulator.

64 transition (EMT)-associated genes, including MMP-9 and Snail.

65 The increased and aberrant expression of MMP-9 and specific MMP-9 forms may help explain the cons

66 we confirmed morphine-induced alterations in MMP-9 and TIMP expression and identified organs, includi

67 mal DNA methylation and an imbalance between MMP-9 and TIMP-1 and -2 lead to ECM remodeling and renal

68 al rigidity providing feedback which affects MMP-9 and TIMP-1 secretion, which may become dysregulate

69 Mechanistically, MMP-9 and VCAM-1 appear to be involved downstream of PDG

70 production of iNOS and arginase, as well as MMP-9 and VEGF.

71 ession of matrix metalloproteinase (MMP) -2, MMP-9 and vimentin.

72 (i.e., matrix metalloproteinase [MMP]-2 and MMP-9) and extracellular matrix metalloproteinase induce

73 ased circulating matrix metalloproteinase 9 (MMP-9) and increased circulating tissue inhibitor of met

74 catalase (CAT), matrix metalloproteinase-9 (MMP-9), and cardiac Troponin-T (cTnT) were evaluated by

75 matically active matrix metalloproteinase 9 (MMP-9), and were capable of mediating potent effects on

76 with a 2.3% decrease (95% CI: -4.3, -0.3) in MMP-9, and a 5% increase in %uMMA was associated with a

77 IL]-1beta, matrix metalloproteinase [MMP]-8, MMP-9, and cathepsin D levels) evaluations were performe

78 stress (MDA and OSI), and proteases (MMP-8, MMP-9, and CtD) that was significantly higher in the kid

79 cted to cause a significant decrease of MDA, MMP-9, and cTnT levels which were found to be significan

80 ed positively with the expressions of MMP-2, MMP-9, and EMMPRIN in gingiva.

81 ough inhibiting integrin alphavbeta6, MMP-2, MMP-9, and ERK phosphorylation by HT29.

82 In particular, MMP-2, MMP-9, and MMP-14 have been reported to be crucial for t

83 NE, MMP-8, MMP-9, and MPO levels were elevated in oGVHD tears when

84 In controls, NE, MMP-9, and MPO significantly correlated with each other

85 hat correlated strongly with elevated MMP-8, MMP-9, and MPO suggests a common neutrophilic source and

86 on studies were performed between NE, MMP-8, MMP-9, and MPO within study groups.

87 MMP-8, MMP-9, and TIMP-1 levels were determined in gingival cre

88 levels of matrix metalloproteinase (MMP)-8, MMP-9, and tissue inhibitor of MP-1 (TIMP-1) in biofluid

89 tin by MMP-2, confirming that PEX9 is not an MMP-9 antagonist.

90 Matrix metalloproteinase 9 (MMP-9) antisense oligonucleotides (ASO) or an MMP inhibi

91 studies of a potent difluorinated probe with MMP-9 are also disclosed and indicate that the structura

92 ) minimal immunoreactive and active Mmp-8 or Mmp-9 are detected on the surface of activated Timp-1(-/

93 MMP-2 and MMP-9 are detected using label free porous silicon (PSi)

94 FGF2 is a known mitogen, and both FGF2/MMP-9 are proangiogenic factors.

95 minal hemopexin domains of pro-Mmp-8 and pro-Mmp-9 are required for their binding to membrane-bound T

96 that MCV sT contributes to the activation of MMP-9 as a result of FBW7 targeting and increases the in

97 e data do not support the inclusion of serum MMP-9 as predictive biomarker for DMD patients.

98 s to investigate Matrix Metalloproteinase-9 (MMP-9) as predictive biomarker for Duchenne.

99 olytic cleavage of hepatic VEGF using either MMP-9 ASO or intraportal MMP inhibitor in 5-week and 10-

100 L-12p40 and high level of metalloprotease 9 (MMP-9) at the late stages of disease.

101 The PMN receptor(s) to which MMP-8 and MMP-9 bind(s) is not known.

102 tingly, late-phase LTP was also decreased by MMP-9 blockade.

103 0% in cellular assays, and IgG L13 inhibited MMP-9 but not MMP-2/-12/-14 and significantly relieved n

104 nstrate that mRNA and protein expressions of MMP-9, but not MMP-2, are significantly higher in AVM ti

105 The serum level of MMP-9, but not MMP-2, is also elevated in AVM patients c

106 The tear film was analyzed for MMP-9 by a commercially available test (InflammaDry; Rap

107 nd achieve ultimate selectivity: They target MMP-9 by allosterically preventing activation of its zym

108 Consistent with MMP-9 cleavage resulting in largely non-amyloidogenic de

109 tigated whether hIAPP fragments arising from MMP-9 cleavage retain the potential to aggregate and cau

110 GCF and serum MMP-8 concentrations, serum MMP-9 concentrations, and serum MMP-8/MMP-1 and MMP-9/MM

111 MMP-9 decreased in parallel to clinical stabilization in

112 tro stimulation of isolated neutrophils with MMP-9 decreased neutrophil apoptosis, indicated by reduc

113 n of collagenases or selective inhibition of MMP-9 decreased pathological vascular permeability in a

114 ast 2-fold upregulated or downregulated with MMP-9 deletion (all P<0.05).

115 These effects were MMP-9 dependent and were reversed in the presence of spe

116 collective results support the necessity of MMP-9-dependent H3NT proteolysis in regulating gene path

117 l mechanism of alcohol craving that involves MMP-9-dependent synaptic plasticity in CeA.

118 (MMP-2), a protease which may interfere with MMP-9 detection.

119 GST-PEX9 inhibited MMP-9-driven gelatin proteolysis, measured by gelatin zy

120 MMP-9 efficiently degrades the extracellular matrix comp

121 MMP-9 expression and MMP-9/TIMP-1 ratio were similar amo

122 e show that fibrotic rigidities downregulate MMP-9 expression and secretion, and also upregulate secr

123 HFHF rats, the MMP inhibitor reduced active MMP-9 expression by 97%, ameliorated histologic evidence

124 ct volume, edema, inflammation, and vascular MMP-9 expression compared with IR and sham groups.

125 d epidermal growth factor receptor-regulated MMP-9 expression via ERK1/2, which resulted in cleavage

126 MMP-2 and MMP-9 expression was reduced in the skin of doxycycline-

127 ation accompanied by a decrease in MMP-2 and MMP-9 expression within the aortic wall in doxycycline-t

128 y, migration and invasion, reduced MMP-2 and MMP-9 expression, and reduced N-cadherin expression, but

129 XLOC_006277 knockdown suppressed MMP-8 and MMP-9 expression, both associated with heart lesions.

130 -9 gene at position -1562, which upregulates MMP-9 expression, correlated with increased motivation f

131 blasts, RHAMM promoted ERK1/2 activation and MMP-9 expression, whereas in keratinocytes, RHAMM suppre

132 g PMNs, and its removal by PMN-MP-associated MMP-9 facilitates PMN trafficking across epithelial laye

133 gated gains in secreted proteases, MMP-2 and MMP-9, following radiation.

134 nd aberrant expression of MMP-9 and specific MMP-9 forms may help explain the constitutive vascular r

135 These granules are involved in trafficking MMP-9 from the stroma to the epithelium to promote lumin

136 ix metalloproteinases (MMP)-1, MMP-3, MMP-8, MMP-9, from baseline to week 2; regulated on activation,

137 investigation of the effects of the loss of MMP-9 function on pancreatic islets uncovers a deteriora

138 (TIMP)-1, matrix metalloproteinase (MMP)-2, MMP-9, Galectin-3 (Gal-3), N-terminal propeptide of coll

139 Finally, C/T polymorphism of MMP-9 gene at position -1562, which upregulates MMP-9 ex

140 primers, we found a significant increase in MMP-9 gene expression in the tumor-reactive stroma durin

141 etylation of H3K18 as a central regulator of MMP-9 H3NT protease activity both in vitro and at H3NT c

142 MMP-9 has been shown to play a detrimental role in many

143 dysregulation of matrix metalloproteinase-9 (MMP-9) has been implicated in multiple essential roles i

144 isease, involves matrix metalloproteinase 9 (MMP-9), IL-17, and IL-23 release from infiltrated inflam

145 this antiulcer drug reduces IL-6, MMP-1, and MMP-9 immunoexpression in gingiva with induced periodont

146 the relationship between IL-6/MMP-1 and IL-6/MMP-9 immunoexpression was evaluated.

147 er and induces reduction of IL-6, MMP-1, and MMP-9 immunoexpression, reinforcing the idea that the be

148 ocess surface and number of IL-6, MMP-1, and MMP-9-immunolabeled cells in the gingival mucosa were qu

149 AP-positive osteoclasts and IL-6, MMP-1, and MMP-9-immunolabeled cells was significantly lower than i

150 ation products, adenoviral overexpression of MMP-9 in amyloid-prone islets reduced amyloid deposition

151 d cause toxicity, and whether overexpressing MMP-9 in amyloid-prone islets reduces amyloid burden and

152 ether an 8-week HIIT intervention influences MMP-9 in breast cancer patients undergoing anthracycline

153 ators, TNF-alpha, IL-1 beta, IL-6, MMP-2 and MMP-9 in HCECs exposed to hyperosmotic medium.

154 Thus, MMP-9 in particular could play a role in tubal scarring

155 Concentration of MMP-9 in saliva samples was determined, with linearity i

156 ld be rescued by overexpression of exogenous MMP-9 in the central nucleus of the amygdala (CeA).

157 MMP-9 in the CON group was not significantly changed [11

158 We aimed to validate a tear MMP-9 in-situ immunoassay (InflammaDry) and to identify

159 The results of the MMP-9 in-situ immunoassay varied significantly depending

160 ible function of matrix metalloproteinase-9 (MMP-9) in alcohol addiction because this protein has rec

161 educed levels of matrix metalloproteinase-9 (MMP-9) in the plasma and brains at different time points

162 ysyl oxidase and a second metalloproteinase, MMP-9, in murine optic gliomas relative to normal non-ne

163 (MMP-14, a predominant target in metastasis; MMP-9, in neuropathic pain), beta-secretase 1 (BACE-1, a

164 MMP-9, in particular, is highly dynamically regulated in

165 matrix metalloproteinases (MMPs), MMP-8 and MMP-9, in the wounds of db/db mice.

166 GST-B1 also inhibited gelatin degradation by MMP-9, indicating that these regions are responsible for

167 show that the recombinant FN domain inhibits MMP-9-induced TGF-beta activation and fibroblast differe

168 We found that liver-selective MMP-9 inhibition accelerated liver regeneration after pa

169 Here, we investigated whether MMP-9 inhibition also interferes with threat memory reco

170 Liver-selective MMP-9 inhibition enhances VEGF-sdf1 signaling and recrui

171 Liver-selective MMP-9 inhibition largely abolished warm ischemia-reperfu

172 Liver-selective MMP-9 inhibition markedly increased recruitment and engr

173 Liver-selective MMP-9 inhibition may be a therapeutic tool for liver inj

174 Liver-selective MMP-9 inhibition prevented VEGF cleavage and doubled pro

175 extended hepatectomy model, liver-selective MMP-9 inhibition restored liver sinusoidal endothelial c

176 Liver-selective MMP-9 inhibition to protect against proteolytic cleavage

177 esis for this study was that liver-selective MMP-9 inhibition would protect the hepatic VEGF-sdf-1 si

178 nhibitor were used to induce liver-selective MMP-9 inhibition.

179 Coinjection of an MMP-9 inhibitor, but not an MMP-2 inhibitor, reduced per

180 Lupin seeds contain the most efficient MMP-9 inhibitors of all legume seeds analyzed, inhibitin

181 Specific MMP-9 inhibitors would be a promising treatment for AVMs

182 min and globulin fractions were screened for MMP-9 inhibitors, using a fluorometric assay and gelatin

183 udies, we also report that the expression of MMP-9 is significantly decreased in activated HSCs in fi

184 Matrix metalloproteinase-9 (MMP-9) is active in islets and cleaves hIAPP.

185 Matrix metalloproteinase-9 (MMP-9) is required for structural synapse remodeling inv

186 These plastic changes were impaired in MMP-9 knockout mice.

187 Mice devoid of MMP-9 (MMP-9 knockout) drank as much alcohol as wild-type anima

188 IL-6, matrix metalloproteinase (MMP)-8, and MMP-9 levels among habitual gutka chewers and non-chewer

189 ng clinical periodontal parameters and serum MMP-9 levels and MMP-9/TIMP-1 ratio in systemically heal

190 Autopsy-derived PFC samples show elevated MMP-9 levels in antidepressant-treated MDD patients comp

191 Chronic venlafaxine increases MMP-9 levels in murine cortex, and increases both pyrami

192 s of natural history cohorts showed elevated MMP-9 levels in patients and a significant increase over

193 ogen Screening, Inc, Sarasota, FL) detecting MMP-9 levels of more than 40 ng/ml.

194 ng clinical periodontal parameters and serum MMP-9 levels or salivary MPO, NE levels, and MMP-9/MMP-1

195 tension study clarified that the decrease in MMP-9 levels was not predictive of treatment response.

196 nd whole salivary IL-6, IL-1beta, MMP-8, and MMP-9 levels were higher among gutka chewers than non-ch

197 Serum MMP-9 levels were lower in healthy women with gingivitis

198 migration, and invasion, increased MMP-2 and MMP-9 levels, enhanced N-cadherin, but reduced E-cadheri

199 Chemical treatments of MMP-9 markedly inhibited MCV sT-induced cell migration a

200 rom the C-terminal region, via the action of MMP-9 (matrix metalloproteinase 9).

201 Thus, MMP-9 may release netrin-1 fragments from the extracellu

202 MMP-9 may serve as the biochemical culprit to target and

203 Mice devoid of MMP-9 (MMP-9 knockout) drank as much alcohol as wild-typ

204 markers including IL-6, COX-2, iNOS, MMP-3, MMP-9, MMP-13 and ADAMTS-4 in IL-1beta-treated OA chondr

205 Cells positive for MMP-9, MMP-13, and alpha-SMA expression were present at

206 -9 concentrations, and serum MMP-8/MMP-1 and MMP-9/MMP-1 molar ratios were significantly higher in Gg

207 MMP-9 levels or salivary MPO, NE levels, and MMP-9/MMP-1 ratio.

208 hemopexin domain fail to bind to Mmp-8(-/-)x Mmp-9(-/-) murine PMNs.

209 ng of pro-Mmp-8 and pro-Mmp-9 to Mmp-8(-/-)x Mmp-9(-/-) murine PMNs.

210 Unlike full-length pro-Mmp-8 and pro-Mmp-9, mutant pro-Mmp proteins lacking the COOH-terminal

211 with controls were BPI, ITGAM, CAP37, PCM1, MMP-9, MZB1, UGTT1, PLG, RAB1B, HSP90B1.

212 MMP-9/neutrophil gelatinase-associated lipocalin (NGAL)

213 accumulation of apoptotic neutrophils in the MMP-9 null group compared with wild-type group.

214 Infarct regions from wild-type and MMP-9 null mice (n=8 per group) analyzed by glycoproteom

215 ified as having the highest fold increase in MMP-9 null mice.

216 SD-95 expression in the cortex of WT but not MMP-9-null mice.

217 ocalized expression of TIMP-1 with MMP-8 and MMP-9 on peripheral blood PMN surfaces.

218 esis-related factors (CD26, FGF, HGF, MMP-8, MMP-9, OPN, PF4, SDF-1) and cytokines (IL-1ra, IL-16) in

219 post-myocardial infarction macrophages with MMP-9 or a CD36-blocking peptide reduced phagocytic capa

220 NJ0966 had no effect on MMP-1, MMP-2, MMP-3, MMP-9, or MMP-14 catalytic activity and did not inhibit

221 y images showed uniform distribution of anti-MMP-9 over the sensor chip.

222 4 mm (P < 0.01), and mean concentrations of MMP-9 (P < 0.001) and IL-1beta (P < 0.01) were significa

223 ant positive correlations were found between MMP-9 (P = 0.0198) and IL-1beta (P = 0.0047) levels and

224 Seed proteins include potent inhibitors of MMP-9, particularly low molecular mass proteins.

225 mponent gelatin, and the hemopexin domain of MMP-9 (PEX9) inhibits this degradation.

226 between mGluR5, NO production, or MMP-2 and MMP-9 pharmacologically or genetically is sufficient to

227 er randomization, aldosterone, sST2, TIMP-1, MMP-9, PINP, and PIIINP had decreased more in the sacubi

228 The activity of MMP-2 and MMP-9, predicted to be decreased in DN, was investigated

229 In contrast to other known H3NT proteases, MMP-9 primarily cleaved H3K18-Q19 in vitro and in cells.

230 ration of peripheral immune cells, including MMP-9-producing neutrophils/macrophages, resulting in la

231 rophage expansion, inflammatory cytokine and MMP-9 production and mitigates AAA development.

232 It is likely that the aberrantly accelerated MMP-9 proteolysis during neurogenesis is a biochemical r

233 Using MMP-9 proteolysis of the wild-type, CIP, and control pep

234 nt sequence is severalfold more sensitive to MMP-9 proteolysis relative to the wild type.

235 Hepatic MMP-9 proteolytically cleaved VEGF after partial hepatec

236 The MMP-2 and MMP-9 quantification correlated well with the ELISA.

237 ork, we addressed the potential relevance of MMP-9 recruitment to and activity at the surface of fibr

238 0, favor neutrophil- and monocyte-associated MMP-9 release and disease relapse and opened new therape

239 naling on neutrophils, resulting in enhanced MMP-9 release, and unexpectedly revealed genetic polymor

240 Thus, the LRx-induced increase in MMP-9 removes constraints on structural and functional p

241 Moreover, MMP-9 results correlated with the number of obstructed m

242 Thus, the MMP-9 results indicated a clinically significant inflamm

243 The MMP-9 results were increased significantly in women (P <

244 (40.4%) and in 3 of 54 controls (5.6%), the MMP-9 results were positive.

245 mphocytes, responded to CXCL10 by increasing MMP-9 secretion through the activation of extracellular

246 Finally, CXCL10-increased MMP-9 secretion was inhibited by methylprednisolone and

247 c42 GTPase activity, MT1-MMP expression, and MMP-9 secretion.

248 ) expression and matrix metalloproteinase-9 (MMP-9) secretion by these cells.

249 nd inhibition of matrix metalloproteinase-9 (MMP-9) secretion.

250 ve binding experiments showed that Mmp-8 and Mmp-9 share binding sites on murine PMN surfaces.

251 promote invasion through a FAK>p130Cas>c-Jun>MMP-9 signaling axis.

252 High MMP-9 staining alone (P = .001) or coexistent with low T

253 TNF-alpha and MMP-9 staining did not reveal any significant difference

254 rction, which identified CD36 as a candidate MMP-9 substrate.

255 EX9 did not prevent the degradation of other MMP-9 substrates, such as a fluorogenic peptide, alphaB

256 ing a low-cost, disposable sensor system for MMP-9 suitable for home-monitoring of inflammation.

257 e findings were correlated to results of the MMP-9 test in tears.

258 expectedly revealed genetic polymorphisms in MMP-9 that alter activity.

259 ur data reveal a new cell-signaling role for MMP-9 through CD36 degradation to regulate macrophage ph

260 Saliva MMP-8, MMP-9, TIMP-1, and MPO concentrations distinguished peri

261 ted by pack years of smoking, whereas saliva MMP-9, TIMP-1, and MPO were mostly affected by time sinc

262 dontal parameters and serum MMP-9 levels and MMP-9/TIMP-1 ratio in systemically healthy patients (P <

263 MMP-9 expression and MMP-9/TIMP-1 ratio were similar among rats with ligature

264 e-treated EAE mice had a significantly lower MMP-9/TIMP-1 ratio, and significantly lower MCT-1 and CD

265 Salivary MMP-9 and NE levels, as well as MMP-9/TIMP-1 ratios, were higher in the systemically hea

266 iomarkers, matrix metalloproteinase (MMP)-8, MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1 an

267 ined for metalloproteinase 2 (MMP-2), MMP-3, MMP-9, tissue inhibitor of metalloproteinases 1 (TIMP-1)

268 The MMP-9/ tissue inhibitor of metalloproteases-1 (TIMP-1) c

269 oxidase (MPO), neutrophil elastase (NE), and MMP-9/tissue inhibitor of MMP-1 (TIMP)-1 ratio in patien

270 in inhibits the binding of pro-Mmp-8 and pro-Mmp-9 to Mmp-8(-/-)x Mmp-9(-/-) murine PMNs.

271 By anchoring MMP-8 and MMP-9 to PMN surfaces, membrane-bound TIMP-1 plays a cou

272 r, we have demonstrated that the addition of MMP-9 to the blood diminishes the protective effect of t

273 We show that recruitment of MMP-9 to the fibroblast cell surface occurs through its

274 s the binding of exogenous pro-Mmp-8 and pro-Mmp-9 to the surface of Timp-1(-/-) PMNs.

275 nal assays suggest that both pro- and active MMP-9 trigger alpha-smooth muscle actin expression in cu

276 , respectively), matrix metalloproteinase-9 (MMP-9), tumor necrosis factor-alpha, plasminogen activat

277 pression of downstream target genes DKK1 and MMP-9, two molecules that promote myeloma progression.

278 o costly MRI scans could be the detection of MMP-9, using a low-cost, disposable sensor system for MM

279 lso down-regulated STAT3 target genes MMP-2, MMP-9, VEGF and Twist1, which are involved in cell migra

280 In HIV-positive individuals, MMP-9 was associated with dolichoectasia only when coexp

281 MMP-9 was confirmed in vitro and in vivo to proteolytica

282 tive correlation between IL-6/MMP-1 and IL-6/MMP-9 was detected in PDSG and PDCimG.

283 MMP-9 was expressed in Escherichia coli BL21 and purifie

284 egradation of Abeta(1-16) by either MMP-2 or MMP-9 was not observed even after prolonged incubation t

285 However, within-group decrease in MMP-9 was observed in the HIIT group [104.3(51.9) to 65.

286 A THPI selective for MMP-2 and MMP-9 was redesigned to incorporate non-native amino aci

287 Gb values for interaction of MMP-9 and anti-MMP-9 were 0.4nM, 680 microRIU and -53.51kJ/mol, respect

288 Levels of VEGF and MMP-9 were consistently higher in VSP patients, with the

289 NA and protein levels of IL-6, TNFalpha, and MMP-9 were elevated in diabetic rats both 2 and 3 weeks

290 Elevated concentrations of GCF MMP-8 and MMP-9 were found in Gg compared with Gh group (P <0.05).

291 dichotomy, recombinant human (rh) MMP-2 and MMP-9 were incubated with Abeta40 and Abeta42, and the r

292 When both MMP-3 and MMP-9 were inhibited, both early- and late-phase LTP was

293 upon by matrix metalloproteinases (MMP-2 and MMP-9), which are up-regulated in heart tissue post-myoc

294 combinant human matrix metalloproteinases-9 (MMP-9), which has been associated with malignant tumor p

295 The collagenase matrix metalloprotease 9 (MMP-9), which is increased in patients with diabetic mac

296 ndent genes, including the gene that encodes MMP-9, which we implicated as a regulator of integrin-de

297 Inhibiting MMP-9 with doxycycline is suggested to attenuate human t

298 ology successfully reduces the expression of MMP-9 within the wounds of diabetic mice, significantly

299 ective compound that inhibited activation of MMP-9 zymogen and subsequent generation of catalytically

300 with a structural pocket in proximity to the MMP-9 zymogen cleavage site near Arg-106, which is disti